Analyst Samantha Semenkow of Citi maintained a Buy rating on BioAge Labs, Inc., with a price target of $52.00.

Claim 55% Off TipRanks

• Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
• Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

Samantha Semenkow has given his Buy rating due to a combination of factors tied to both valuation and pipeline strength. Despite the recent sell-off driven by Novo’s ZEUS trial failure, he views the market reaction as excessive, with BioAge’s enterprise value now near zero relative to the potential of its NLRP3 inhibitor platform and broader inflammatory disease strategy.

Moreover, he highlights that upstream IL-1β and NLRP3 inhibition remain scientifically validated targets, supporting continued development across cardiovascular and non-cardiovascular indications. With upcoming Phase 2 data for BGE-102, a planned ophthalmology study, and sufficient cash to fund another proof-of-concept trial, he sees a compelling risk/reward profile that justifies a Buy rating and a triple-digit expected return potential.

Semenkow covers the Healthcare sector, focusing on stocks such as Nektar Therapeutics, Larimar Therapeutics, and Wave Life Sciences. According to TipRanks, Semenkow has an average return of 4.7% and a 48.85% success rate on recommended stocks.

In another report released today, Jefferies also maintained a Buy rating on the stock with a $21.00 price target.